May 16, 2023
Leipzig, 18-20th May 2023 – 94. Jahresversammlung der DGHNO-KHC, Congress Center Leipzig The German Society of Oto-Rhino-Laryngology, Head and Neck Surgery is dedicated to the advancement of scientific and clinical knowledge in its fields. AudioCure CEO, Reimar...
Jan 13, 2023
12th Feb: Efficacy of AC102 for the Preservation of Residual Hearing following Cochlear Implantation Dr. Michael Nieratschker from Allgemeines Krankenhaus Medical University of Vienna, Austria will present preclinical results performed in a model of electrode...
Oct 16, 2022
International Phase 2 study investigates efficacy, safety and tolerability of AC102 in patients with sudden hearing loss at up to 45 European centers This is another important milestone on the way to a causal treatment of spontaneous hearing loss, which has a high...
Jun 7, 2022
At the start of the Phase II clinical trial, AudioCure Pharma GmbH will provide their newest insights on the mode of action of lead candidate AC102 at the 2nd Summit in Boston from 20-23 June 2022. AC102 is AudioCure’s clinical Phase I tested lead candidate for...
Sep 7, 2021
Phase I study confirms safety and tolerability of AC102 in patients with sudden hearing loss This is another important milestone that clears the way for a Phase 2 study evaluating AC102 in patients with sudden hearing loss Berlin, 7 September 2021 – AudioCure...
Mar 23, 2021
The FDA has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may become of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural hearing loss (SSNHL). Comprehensive...
